087010 - Peptron, Inc.

087010 Summary

Biopharma

Stock Price & Overview

₩157,300 +10,700 (+7.30%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩157,300 ≈ US$112 · Market cap ₩3.7tn (≈ $2.6bn)

087010 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	5.6	3.2	3.3	5.8	6.6	3.1	1.8	3.9	3.2	3.1	2.8
Cost of Revenue	4.1	2.0	2.2	2.5	2.1	2.0	1.1	2.4	2.0	1.9	1.9
Gross Profit	1.5	1.1	1.1	3.3	4.5	1.1	0.7	1.5	1.2	1.2	0.9
Selling, General & Administrative	22.8	17.6	17.0	18.5	20.2	18.7	13.4	9.4	6.0	4.8	3.8
Operating Income	-21.3	-16.5	-15.9	-15.2	-15.7	-17.6	-12.7	-7.9	-4.8	-3.6	-2.9
Finance Income	8.6	0.7	0.2	0.4	0.5	0.1	0.4	4.1	0.5	0.5	0.1
Finance Costs	1.4	3.0	0.4	0.3	0.3	0.7	5.4	—	—	0.1	0.1
Pretax Income	-14.3	-21.6	-15.9	-15.1	-15.3	-18.3	-17.6	-3.7	-4.5	-3.1	-2.8
Income Tax Expense	-0.5	0.4	-0.0	-0.0	-0.2	0.0	0.1	0.0	-0.0	0.1	-0.0
Net Income	-13.8	-22.0	-15.9	-15.1	-15.0	-18.4	-17.7	-3.7	-4.4	-3.2	-2.7
Total Comprehensive Income	-14.6	-22.1	-16.1	-9.3	-15.0	-18.5	-17.2	-3.8	-4.3	-3.5	-2.6

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	179.0	168.9	52.5	68.3	77.9	117.7	61.0	71.8	53.0	57.9	21.7
Current Assets	115.3	126.5	8.0	23.3	32.7	72.1	18.9	31.8	23.1	49.1	14.8
Cash & Cash Equivalents	4.4	1.0	4.3	5.0	4.6	68.0	2.5	1.8	1.0	3.5	0.6
Inventories	1.8	0.3	0.2	0.8	0.7	0.1	0.0	0.0	0.5	0.2	0.0
Trade Receivables	0.6	0.3	0.4	0.4	0.4	0.4	0.1	0.0	0.7	0.3	0.0
Non-current Assets	63.7	42.4	44.5	45.0	45.2	45.6	42.1	40.0	30.0	8.8	6.8
Property, Plant & Equipment	27.6	26.9	38.7	40.7	38.1	40.8	40.3	37.9	28.5	7.1	4.7
Intangible Assets	3.2	2.8	1.8	0.7	0.6	0.6	0.9	1.0	1.1	1.2	1.2
Total Liabilities	37.0	17.2	16.4	15.2	15.6	40.6	32.9	26.7	4.1	4.7	4.4
Current Liabilities	7.0	5.1	6.9	10.8	6.6	28.6	1.1	3.0	0.7	0.9	2.9
Non-current Liabilities	30.0	12.1	9.5	4.4	9.0	12.0	31.8	23.7	3.4	3.8	1.5
Total Equity	142.0	151.7	36.1	53.1	62.3	77.1	28.1	45.1	48.9	53.2	17.2
Share Capital	11.7	11.6	10.3	10.3	10.3	10.3	7.7	7.7	3.8	3.7	3.3
Retained Earnings	106.1	-13.5	4.9	20.2	-82.1	-67.1	-48.5	-30.5	-26.7	-22.4	-18.9

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	-20.6	-12.8	-11.0	-11.7	-10.6	-13.6	-9.6	-4.2	-5.6	-2.7	-2.4
Cash from Investing Activities	-0.3	-127.4	11.0	12.1	-25.0	5.5	9.2	-20.5	3.3	-33.4	-10.1
Purchase of Property, Plant & Equipment	2.5	1.0	0.7	1.5	0.7	3.1	5.0	10.1	21.8	2.8	0.2
Cash from Financing Activities	24.3	136.8	-0.9	-0.0	-26.9	73.6	1.0	25.5	-0.1	39.2	12.6
Net Change in Cash	3.3	-3.2	-0.8	0.4	-62.5	65.5	0.6	0.8	-2.6	3.1	0.1

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	1.4	2.0	1.0	1.6	1.4	1.6	1.5	0.6	0.5	0.5
Cost of Revenue	2.0	1.4	2.3	0.6	0.6	0.6	0.8	0.4	0.4	0.4
Gross Profit	-0.5	0.6	-1.3	1.0	0.8	1.0	0.8	0.1	0.1	0.1
Selling, General & Administrative	7.4	6.4	4.4	7.2	5.8	5.4	4.3	4.8	4.4	4.1
Operating Income	-7.9	-5.8	-5.7	-6.2	-5.0	-4.4	-3.5	-4.7	-4.3	-4.0
Finance Income	1.6	0.9	1.5	4.5	1.4	1.2	0.5	0.1	0.1	0.0
Finance Costs	1.5	1.6	0.9	0.4	0.1	0.1	2.2	0.1	0.5	0.1
Pretax Income	-7.7	-6.1	-5.2	-2.1	-3.7	-3.3	-4.9	-4.8	-7.8	-4.0
Income Tax Expense	0.0	0.0	-0.5	0.1	0.1	0.0	0.1	-0.0	0.4	—
Net Income	-7.7	-6.1	-4.7	-2.0	-3.8	-3.3	-5.0	-4.8	-8.2	-4.0
Total Comprehensive Income	-7.7	-6.1	-5.5	-1.4	-4.4	-3.3	-5.1	-4.6	-8.4	-4.0

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	168.0	174.5	179.0	183.7	162.0	164.8	168.9	40.6	41.9	49.9
Current Assets	82.4	93.5	115.3	115.7	107.0	122.2	126.5	7.1	8.4	6.0
Cash & Cash Equivalents	12.3	10.6	4.4	1.5	0.9	0.7	1.0	1.5	0.7	1.8
Inventories	1.8	2.2	1.8	0.2	0.4	0.2	0.3	0.1	0.2	0.3
Trade Receivables	2.9	0.9	0.6	0.3	0.3	0.4	0.3	0.3	0.3	0.4
Non-current Assets	85.6	80.9	63.7	68.0	55.0	42.7	42.4	33.5	33.4	43.9
Property, Plant & Equipment	33.6	33.9	27.6	26.9	26.8	26.5	26.9	27.1	27.4	38.4
Intangible Assets	3.2	3.1	3.2	3.2	3.1	2.9	2.8	2.5	2.2	2.0
Total Liabilities	38.5	38.5	37.0	37.4	18.0	16.5	17.2	19.9	16.6	17.8
Current Liabilities	9.0	7.7	7.0	7.3	4.8	4.2	5.1	7.0	7.3	8.2
Non-current Liabilities	29.5	30.8	30.0	30.1	13.2	12.3	12.1	12.9	9.3	9.6
Total Equity	129.5	136.0	142.0	146.3	144.0	148.4	151.7	20.7	25.3	32.1
Share Capital	11.7	11.7	11.7	11.7	11.6	11.6	11.6	10.3	10.3	10.3
Retained Earnings	92.2	99.9	106.1	111.1	112.5	116.9	-13.5	-8.1	-3.5	0.9

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	-3.6	-4.4	-4.9	-7.3	-3.9	-4.5	-2.4	-4.0	-3.4	-2.9
Cash from Investing Activities	5.4	10.6	8.1	-16.7	4.2	4.1	-130.7	1.3	1.6	0.4
Purchase of Property, Plant & Equipment	0.7	6.6	1.5	0.4	0.6	0.0	0.3	0.3	-0.0	0.4
Cash from Financing Activities	-0.1	-0.1	-0.3	24.7	-0.1	-0.0	132.6	3.5	0.7	-0.0
Net Change in Cash	1.7	6.2	2.8	0.7	0.2	-0.4	-0.4	0.8	-1.1	-2.5

Separate / parent-only (OFS) — this company files no consolidated statements, from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

087010 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	5.6	+78.8%	-1.0%	+12.5%	+7.2%
Operating income	-21.3	—	—	—	—
Net income	-13.8	—	—	—	—
EPS	₩-593	—	—	—	—
Operating cash flow	-20.6	—	—	—	—
Shareholders' equity	142.0	-6.4%	+38.8%	+13.0%	+23.5%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

087010 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	27.2%	35.1%	34.1%	57.1%	68.6%	36.4%
Operating margin	-377.3%	-524.3%	-475.3%	-261.9%	-236.4%	-564.2%
Net margin	-245.3%	-699.0%	-476.4%	-259.1%	-227.1%	-589.0%
Return on equity	-9.4%	-23.5%	-35.7%	-26.1%	-21.6%	-34.9%
Return on assets	-7.9%	-19.9%	-26.4%	-20.6%	-15.4%	-20.6%
Operating cash flow / revenue	-365.3%	-405.0%	-328.4%	-201.6%	-160.2%	-434.2%
Capex / revenue	44.3%	32.0%	21.9%	26.2%	10.5%	99.3%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 087010

Symbol	Last Price
028300HLB Co., Ltd.	₩33,750 +2.9%
298380ABL Bio Inc.	₩71,400 +5.6%
000250Samchundang Pharm	₩157,000 +1.0%
141080LigaChem Biosciences Inc.	₩92,000 +4.2%
145020Hugel, Inc.	₩244,000 +1.5%
302440SK Bioscience Co., Ltd.	₩37,900 +0.4%
009420Hanall Biopharma Co., Ltd.	₩54,700 +1.5%
310210Voronoi, Inc.	₩153,000 +3.9%
214370Caregen Co., Ltd.	₩44,500 +1.5%
347850D & D Pharmatech, Inc.	₩49,200 +1.4%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.